# PALVELLA THERAPEUTICS, INC.: SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | PALVELLA THERAPEUTICS, INC. |
| Location | WAYNE, PA |
| Project | SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations |
| Project number | 5R01FD008196-03 |
| Mechanism | R01 |
| Institute | Food and Drug Administration |
| Award | $484,481 |
| Awarded | 2026-09-17 |
| Project period | 2024-09-20 to 2028-08-31 |
| UEI | KTH1B7KWRCN9 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11403007). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.